Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Feb 8;76(3):e1177-e1185.
doi: 10.1093/cid/ciac643.

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

Ahmed M Musa  1 , Jane Mbui  2 , Rezika Mohammed  3 , Joseph Olobo  4 , Koert Ritmeijer  5 , Gabriel Alcoba  6 , Gina Muthoni Ouattara  7 , Thaddaeus Egondi  7 , Prossy Nakanwagi  7 , Truphosa Omollo  7 , Monique Wasunna  7 , Luka Verrest  8 , Thomas P C Dorlo  8 , Brima Musa Younis  1 , Ali Nour  1 , Elmukashfi Taha Ahmed Elmukashfi  1 , Ahmed Ismail Omer Haroun  1 , Eltahir A G Khalil  1 , Simon Njenga  2 , Helina Fikre  3 , Tigist Mekonnen  3 , Dagnew Mersha  9 , Kasaye Sisay  9 , Patrick Sagaki  10 , Jorge Alvar  11 , Alexandra Solomos  11 , Fabiana Alves  11
Affiliations
Clinical Trial

Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial

Ahmed M Musa et al. Clin Infect Dis. .

Abstract

Background: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa.

Methods: An open-label, phase 3, randomized, controlled trial was conducted in adult and pediatric patients at 7 sites in eastern Africa. Patients were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days). The primary endpoint was definitive cure after 6 months.

Results: Of 439 randomized patients, 424 completed the trial. Definitive cure at 6 months was 91.2% (155 of 170) and 91.8% (156 of 170) in the PM/MF and SSG/PM arms in primary efficacy modified intention-to-treat analysis (difference, 0.6%; 97.5% confidence interval [CI], -6.2 to 7.4), narrowly missing the noninferiority margin of 7%. In the per-protocol analysis, efficacy was 92% (149 of 162) and 91.7% (155 of 169) in the PM/MF and SSG/PM arms (difference, -0.3%; 97.5% CI, -7.0 to 6.5), demonstrating noninferiority. Treatments were well tolerated. Four of 18 serious adverse events were study drug-related, and 1 death was SSG-related. Allometric dosing ensured similar MF exposure in children (<12 years) and adults.

Conclusions: PM/MF and SSG/PM efficacies were similar, and adverse drug reactions were as expected given the drugs safety profiles. With 1 less injection each day, reduced treatment duration, and no risk of SSG-associated life-threatening cardiotoxicity, PM/MF is a more patient-friendly alternative for children and adults with primary visceral leishmaniasis in eastern Africa.

Clinical trials registration: NCT03129646.

Keywords: eastern Africa; miltefosine; paromomycin; phase 3 trial; visceral leishmaniasis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Patient disposition. aThe most common reasons for screening failure were negative parasitology (746 patients, 22.6%), laboratory abnormalities (338 patients, 13%), age <4 years or >50 years (329 patients, 12.7%), severe malnourishment (230 patients, 8.9%), or other reasons (245 patients, 9.4%). One patient died during screening. bOne additional patient discontinued the study treatment due to AEs but did not receive rescue medication and completed the study. cThree patients missed the EOT (day 28) visit but were included at later visits. Abbreviations: AE, adverse event; D, day; EOT, end of treatment; MF, miltefosine; PM, paromomycin; SSG, sodium stibogluconate.
See this image and copyright information in PMC

References

    1. World Health Organization . Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap. Wkly Epidemiol Rec 2021; 35:401–20.
    1. Harhay MO, Olliaro PL, Vaillant M, et al. Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia. Am J Trop Med Hyg 2011; 84:543–50. - PMC - PubMed
    1. World Health Organization , Technical Report Series 949. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010:1–186.
    1. Omollo R, Alexander N, Edwards T, et al. Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial. Trials 2011; 12:166. - PMC - PubMed
    1. Wasunna M, Njenga S, Balasegaram M, et al. Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial. PLoS Negl Trop Dis 2016; 10:e0004880. - PMC - PubMed

Publication types

Associated data